As a leader in health and agriculture, something is always happening at Bayer in the U.S. and in the countless communities we serve. Take a look below—and check back often—to explore some of our most exciting news and stories as they emerge.
These contacts are for media inquiries only.
All other inquiries can be directed to:
Bayer Corporation
100 Bayer Boulevard
Whippany, NJ 07981
Phone: 862-404-3000
Click here for general inquiries.
Click here to report an adverse event.
Click here if you are a US healthcare professional seeking medical information.
General U.S. Media Inquiries
USmediainquiries@bayer.com
Click here for Global Media Inquiries
Nicole Hayes
Director, U.S. Communications
201-421-5268
Nicole.Hayes@bayer.com
Brian Leake
Director, External Communications
314-370.3285
brian.leake@bayer.com
Kyel Richard
Deputy Director, External Communications
573-356-0241
kyel.richard@bayer.com
Sue Ann Pentecost
U.S. Communications
910-221-6446
Sueann.pentecost@bayer.com
Bayer Releases Statement on Judge’s Ruling on False Advertising Suit Against J&J and Janssen Biotech
Bayer has released a statement regarding the ruling on the preliminary injunction it filed against J&J and Janssen Biotech
“This decision comes at a very early stage in the case and only addresses the preliminary, pre-trial relief sought by the company. Bayer continues to believe the full body of evidence supports its false advertising claims and looks forward to the Court’s determination on the merits of the case. The company maintains that J&J’s superiority claims are false, misapply real-world evidence, mislead prescribers and patients, and are intended to increase its market share in a concentrated and increasingly competitive prostate cancer treatment market.”
Passage of New Kentucky Bill a Win for Farmers
We applaud Kentucky for joining Georgia and North Dakota as states that prioritize farmers over the litigation industry. This legislation is a testament to the important work of farmers and agriculture groups in the state who work tirelessly to advocate for crucial tools that underpin food security and keep grocery prices in check.
Statement in Response to White House Action Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides
President Trump’s Executive Order reinforces the critical need for U.S. farmers to have access to essential, domestically produced crop protection tools such as glyphosate. We will comply with this order to produce glyphosate and elemental phosphorus.
Bayer Statement on mRNA Lawsuits
Bayer did not manufacture and has never manufactured the COVID vaccine. This lawsuit alleges the defendants infringed on patented innovations owned by Bayer which increase mRNA stability and which Bayer initially used [for agricultural purposes]. The defendants’ unlicensed use of Bayer’s intellectual property enabled them to address mRNA instability, solving one of the biggest challenges they faced during vaccine development.
Statement on RoundUp Active Ingredient Safety
American Agriculture at Risk- An Open Letter on Glyphosate
Bayer statement on Monsanto/glyphosate trial
Bayer statement on Xarelto March 25, 2019
Kogenate FS Recall Healthcare Provider Notification
Kogenate FS Recall Bayer Response to NHF/HFA
Statement on Delaware Supreme Court’s Decision (Nov. 2023)
“Bayer is pleased with the Delaware Supreme Court’s decision to affirm the Chancery Court’s dismissal with prejudice of Merck’s meritless case against the company. The Supreme Court’s affirmance is based on the same reasons given by the Chancery Court, which found that Merck was solely liable and responsible for all product-liability claims relating to the time before the closing of the Purchase Agreement between the two companies under its terms.”
